Michael Hoelscher

Prof. Dr. Michael Hoelscher serves as Professor and Coordinator of the Tuberculosis Partner Site at Ludwig Maximilian University of Munich, acting as Speaker for Munich at the University Hospital. His work integrates HIV and tuberculosis research within the German Center for Infection Research (DZIF) framework.

His primary research spans Tuberculosis drug development, HIV clinical trials, and infectious disease pharmacology. He directs the MycoDrugs and Trials platform for preclinical tuberculosis drug evaluation using in vitro test systems and aerosol inhalation mouse models, while co-leading the International Clinical Trials Unit focused on HIV research in African cohorts. His methodology emphasizes translational approaches from laboratory models to human applications.

Recent publications demonstrate expertise in tuberculosis drug pharmacokinetics within lesions, as evidenced by the 2025 Nature Communications study on BTZ-043's efficacy in murine models. His work consistently bridges preclinical drug testing with clinical trial design for antimicrobial therapies.

No scientific awards were documented in the provided materials.

No student advisees were listed in the source text. His grant-related activities center on DZIF-funded initiatives including the International Clinical Trials Unit, which coordinates multicenter HIV studies in Africa and provides access to biobanks and patient cohorts for translational research.

He leads the MycoDrugs and Trials working group and contributes to the International Clinical Trials Unit within DZIF, both critical components of Germany's national infection research infrastructure focused on tuberculosis and HIV.